Organic Selenide and DPPD Mixture for Breast Cancer Chemoprevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current breast cancer therapies lack effective synthetic antioxidants with novel chemical structures, and there is a need for new pharmaceutical compositions to address oxidative stress mechanisms involved in breast cancer progression and metastasis.
Innovation Solution
Development of novel organic selenide compounds and their use in conjunction with N,N′-Diphenyl-1,4-phenylenediamine (DPPD) as a chemopreventive mixture to induce an antioxidant response and treat breast cancer by reducing oxidative stress markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antioxidant compounds (vitamins, selenium) are used for breast cancer therapy, then antioxidant activity is achieved, but therapeutic effectiveness is insufficient due to lack of novel synthetic structures
Solution Approach 1:
The patent combines DPPD (a synthetic antioxidant) with organic selenide compounds to create a composite chemopreventive mixture. This composite approach leverages the hydrogen donation capability of DPPD alongside the antioxidant properties of organic selenides, achieving enhanced therapeutic effectiveness against breast cancer while addressing the limitation of conventional single-antioxidant therapies.
Solution Approach 2:
The invention modifies the chemical structure parameters by introducing novel organic selenide compounds with specific molecular configurations (compounds of formula I with various R1 and R2 substituents). These structural parameter changes create new synthetic antioxidants that differ from conventional vitamins and selenium, providing enhanced therapeutic potential while maintaining adaptability.
2Object-affected harmful factors
If oxidative stress mechanisms are targeted in breast cancer, then cancer progression and metastasis are affected, but existing antioxidants lack sufficient potency to effectively reduce oxidative stress markers
Solution Approach 1:
DPPD acts as an intermediary antioxidant compound that donates hydrogen to radical species, thereby reducing oxidative stress. The patent positions DPPD as a mediator between the organic selenide compounds and the oxidative stress pathways in breast cancer cells, enhancing the overall antioxidant effect and potency against harmful oxidative markers.
Solution Approach 2:
The combination of DPPD and organic selenide compounds creates a composite antioxidant system with synergistic effects. This composite mixture demonstrates enhanced potency in reducing oxidative stress markers compared to individual antioxidants, effectively addressing the insufficient potency of existing antioxidant therapies.
3Reliability
If synthetic antioxidants with novel structures are developed, then therapeutic potential is enhanced, but pharmaceutical composition complexity increases
Solution Approach 1:
The patent segments the pharmaceutical composition into distinct components: DPPD as the primary synthetic antioxidant and organic selenide compounds (formula I with specific R1 and R2 groups) as secondary agents. This segmentation allows for standardized manufacturing of each component while maintaining the overall therapeutic efficacy of the combination, thereby managing composition complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The organic selenide compounds, when used alone or with DPPD, provide a therapeutically effective chemopreventive effect, reducing breast cancer oxidative stress markers and potentially treating breast and prostate cancers through synergistic action.
Implementation Method 1
DPPD antioxidant activity was attributed to its hydrogen donation capability to radical species, minimizing ROS production and dampening cells' apoptosis
Data Source
AI summary
Novel organic selenide compounds that can be used as a chemopreventive mixture against breast cancer. These compounds and compositions may be used alone or in conjunction with DPPD. Likewise, the present subject matter relates to the use of N, N′-Diphenyl-1,4-phenylenediamine (DPPD) as a synthetic antioxidant supplementation to enhance breast cancer complications.